Merck & Company, Inc.
MRK
Positions held
Your positionsMRK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Merck's strong market position in the healthcare sector, particularly in drug manufacturing, showcases its competitive advantage and potential for growth.
- Merck's revenue for 2025 is projected at $65 billion, reflecting a consistent upward trend in sales.
- The company reported a net income of $18.25 billion for 2025, indicating robust profitability.
- Regulatory challenges and competition in the pharmaceutical industry may impact Merck's future growth and profitability.
- Merck's operating margin for Q2 2026 was -2.6%, highlighting ongoing operational difficulties.
- The trailing P/E ratio of 112.65 suggests that the stock may be overvalued compared to its earnings potential.
Fundamentals
| Market cap | $351.28B | Enterprise value | $398.10B | Trailing P/E | 113.00 | Forward P/E | 15.19 |
| PEG | 2.61 | Price / book | 8.38 | Beta | 0.22 | Dividend yield | 2.39% |
| Revenue growth | 5.1% | Earnings growth | — | Gross margin | 75.9% | Operating margin | -0.2% |
| Profit margin | 4.8% | ROE | 7.0% | ROA | 11.9% | Debt / equity | 1.28 |
| Current ratio | 1.32 | Free cash flow | $15.17B | Analyst recommendation | buy | Mean target | $157.28 |
| 52w high | $156.92 | 52w low | $82.01 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $16.6B | $16.3B | $16.4B | $17.3B | $15.8B |
| Op margin | -2.6% | -19.7% | 24.8% | 37.9% | 35.1% |
| Net income | -$1.3B | -$4.2B | $3.0B | $5.8B | $4.4B |
| Gross margin | 73.5% | 74.2% | 66.2% | 77.7% | 77.5% |
| Gross profit | $12.2B | $12.1B | $10.8B | $13.4B | $12.2B |
| Operating income | -$433M | -$3.2B | $4.1B | $6.6B | $5.6B |
- Revenue +2% vs prior quarter ($16.6B vs $16.3B).
- Gross margin 73.5% (was 74.2% prior quarter).
- Operating margin expanded to -2.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.0B | $64.2B | $60.1B | $59.3B | — |
| Op margin | 34.0% | 31.5% | 4.9% | 30.8% | — |
| Net income | $18.3B | $17.1B | $365M | $14.5B | — |
| Gross margin | 74.8% | 76.3% | 73.2% | 70.6% | — |
| Gross profit | $48.6B | $49.0B | $44.0B | $41.9B | — |
| Operating income | $22.1B | $20.2B | $3.0B | $18.3B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
2026-10-09 · Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-10-09 · Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
2026-10-09 · Sector Update: Healthcare
2026-10-09 · Moderna stock jumps on planned national cancer vaccine effort
2026-10-09 · Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines
2026-10-09 · BofA Securities Adjusts Merck Price Target to $163 From $166, Maintains Buy Rating
2026-10-09 · Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
2026-10-09 · Wells Fargo Adjusts Price Target on Merck & Co to $165 From $170
2026-10-09 · Should You Be Worried About Pfizer Stock?
2026-10-09 · What Is Going On With Regeneron Stock?
2026-10-08 · Merck (MRK) Wins FDA Approval For WELIREG Plus LENVIMA In Kidney Cancer
Price (daily)
Full chart · RSI · MACD · patterns